Liver resection of noncolorectal secondaries

Lindell, Gert; Ohlsson, Björn; Saarela, Arto; Andersson, Roland; Tranberg, Karl‐Göran

doi:10.1002/(sici)1096-9098(199810)69:2<66::aid-jso4>3.0.co;2-g

Cited by 52 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, a number of different prognostic factors have been shown to be important for survival [17,18,20,21,24,[28][29][30]37]. These differences could possibly be explained by the small number and the diverse clinical characteristics, particularly the origin of the primary tumor, in the patients reported.…”

Section: Discussionmentioning

confidence: 99%

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

Ridder

Walsum

Verhoef

et al. 2012

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Patients with hepatic metastases of melanoma have a very poor prognosis, with a median overall survival of less than 6 months. There are several small heterogeneous studies that have shown an association with prolonged survival in those patients treated with hepatic resection, but the role of surgery remains unclear. We evaluated the safety and efficacy of hepatic resection in a population-based study in the Netherlands for patients with metastatic melanoma and assessed the factors that could affect disease-free and overall survival. Patients with hepatic melanoma metastases who underwent potentially curative resection were identified between 1994 until 2010 using the PALGA database, a nation-wide network and registry of histopathology and cytopathology in the Netherlands. They were retrospectively evaluated for clinical and pathological factors with respect to recurrence and survival using Kaplan-Meier curves to assess survival and univariate regression analysis for the assessment of potential prognostic factors. A total of 32 patients were identified in 15 hospitals, 19 men and 13 women. The median age of the patients at the time of hepatic resection was 52 years (range 27-69). Postoperative complications occurred in five patients (15%), without postoperative mortality. The median follow-up was 21 months (range 3-65). The median disease-free survival was 11 months (range 0-57) and the median overall survival was 29 months (range 4-66). Significant prognostic factors for overall survival in univariate analysis were the distribution and number of metastases, as well as the type of hepatic resection (major or minor). Hepatic resection in patients with resectable metastatic melanoma is safe and might be associated with a prolonged survival in a highly selected group of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

Ridder

Walsum

Verhoef

et al. 2012

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…La resección hepática por MH colorrectales se ha establecido como una práctica segura, con resultados favorables en pacientes cuidadosamente seleccionados [28][29][30] , al igual que ocurre con las MH de tumores neuroendocrinos [4][5][6][7][8] . En el caso de los tumores primarios extraabdominales, por la posible diseminación a regiones extrahepáticas de forma inicial 1,2 , se han planteado, históricamente, dudas sobre la utilidad del tratamiento quirúrgico de las MH 31 .…”

Section: Discussionunclassified

“…Por otro lado, un elevado número de MH proceden de tumores originados fuera de la cavidad abdominal que, por lo general, utilizan la circulación sistémica para alcanzar el hígado, pudiéndose afectar otras localizaciones extrahepáticas con igual probabilidad [1][2][3] . Los primeros trabajos sobre MH no colorrectales tratados mediante resección hepática incluyeron tumores neuroendocrinos y no neuroendocrinos, mostrando mejor pronóstico el grupo de MH de origen neuroendocrino [3][4][5][6][7][8] . Estudios posteriores han confirmado estas diferencias de supervivencia y han excluido a los pacientes con MH de origen neuroendocrino, mostrando que la hepatectomía por MH no colorrectales no neuroendocrinas (MHnCnn) es factible y segura, siendo un tratamiento que puede aumentar la supervivencia, consiguiéndose cifras a 5 años entre el 19 y el 45%…”

Section: Metástasis Hepáticas De Origen No Colorrectal Ni Neuroendocrunclassified

Metástasis Hepáticas De Origen No Colorrectal Ni Neuroendocrino: Tratamiento en Un Hospital De Segundo Nivel

et al. 2015

Rev Chil Cir

View full text Add to dashboard Cite

liver metastases from non-colorectal non-neuroendocrine tumors. treatment in a hospital of second level introduction: Surgical treatment of liver metastases is broadly accepted for colorectal and neuroendocrine tumors. However, the approach to liver metastases of other origins is not well established. The objective is the evaluation of factors that might be associated with better or worse perioperative outcomes (morbidity and mortality) and survival of patients with non-colorectal, non-neuroendocrine liver metastases (nCnnLM) treated surgically in a second level hospital. material and methods: A prospective study of patients with nCnnLM treated surgically or with radiofrequency was completed in San Cecilio University Hospital of Granada, between March 2003 and June 2013. The statistical analysis was made with IBM-SPSS version 21. Statistical significance was set at p ≤ 0.05. Survival data were analyzed by Kaplan-Meier´s method. results: Twenty-two patients with 26 surgeries were analyzed, 19 liver resections, 6 radiofrequency treatments and 1 combined case with surgery and radiofrequency. Operatory mortality was 0% and overage mortality was 23.1%. Univariate analysis only showed statistical significance in two of the factors, presence of positive lymphatic nodes during the surgery of the primary tumor and presence of extra-hepatic disease. Accumulated survival was 81%, 66% and 52% at 1, 2 and 3 years respectively. conclusions: Despite the fact of treating together in the same group several different tumors, the surgical treatment of nCnnLM (with or without radiofrequency) has an acceptable survival rate. Thus, they can be treated with safety when we use a multidisciplinary approach to these patients.

show abstract

“…The reported cases appear frequently associated with other kind of metastatic liver tumour in more large series. Lindlell et al, in the largest series, reported three cases but did not show the outcome [120] . Di Carlo reported a case of long-term survival [121] .…”

Section: Lung Cancermentioning

confidence: 99%

Metastatic lesions to the liver: Surgical indications and techniques

Tejedor¹,

Serrablo²

2013

JST

View full text Add to dashboard Cite

Background: Although there is an established agreement on the advantage of liver resection for metastatic colorectal and neuroendocrine tumours, the role of hepatic surgery in patients with liver metastases from non-colorectal and non-neuroendocrine carcinoma is not well defined. In recent years, despite the poor results, liver metastases suitable for surgery have been treated with resection. The results reported in recent studies support a developing trend toward surgery in this setting. Also, as there are no data that in fact suggest the utility of alternative treatments for these lesions, the role of surgery is reinforced. Methods:A systematic search of English and non-English literature using MEDLINE on the outcomes of patients after surgical treatment of liver metastases from different solid tumours was undertaken. A summary of current surgical techniques used to improve their resectability has been added.Results: All papers reporting median survival and 5-year survival have been selected and presented in tables for most of the primary tumours reviewed. Conclusions:Apart from patients with colorectal and neuroendocrine tumours, liver resection may offer a significative survival advantage in selected patients, mainly those with metastases coming from breast, gastrointestinal stromal tumours, testis, ovary and kidney.

show abstract

Liver resection of noncolorectal secondaries

Cited by 52 publications

References 13 publications

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

Metástasis Hepáticas De Origen No Colorrectal Ni Neuroendocrino: Tratamiento en Un Hospital De Segundo Nivel

Metastatic lesions to the liver: Surgical indications and techniques

Contact Info

Product

Resources

About